WT
RVNC

Washington Trust’s Revance Therapeutics, Inc. RVNC Stock Holding History

Washington Trust’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-507
Closed -$1.54K – 868
2024
Q4 		$1.54K Sell
507
-150
-23% -$653 ﹤0.01% 817
2024
Q3 		$3.41K Sell
657
-973
-60% -$4.84K ﹤0.01% 771
2024
Q2 		$4.19K Hold
1,630
– – ﹤0.01% 760
2024
Q1 		$8.02K Hold
1,630
– – ﹤0.01% 687
2023
Q4 		$14.3K Buy
1,630
+500
+44% +$4.1K ﹤0.01% 602
2023
Q3 		$13K Hold
1,130
– – ﹤0.01% 594
2023
Q2 		$28.6K Hold
1,130
– – ﹤0.01% 500
2023
Q1 		$36.4K Buy
+1,130
New +$35.2K ﹤0.01% 461

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Washington Trust's RVNC Position: Q1 2025 in Review

Washington Trust sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 507 shares — an estimated $1.54K sold.

Washington Trust first reported a position in RVNC in Q1 2023 and held it in 8 quarters. The position peaked at $36.4K in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Washington Trust reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Washington Trust sold 507 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $1.54K.
  • Washington Trust first reported a position in Revance Therapeutics, Inc. in Q1 2023 and held it in 8 quarters.
  • Washington Trust's Revance Therapeutics, Inc. position peaked at $36.4K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Washington Trust's 13F filing for Q1 2025, filed 25 Apr 2025.